80
Participants
Start Date
December 1, 2024
Primary Completion Date
December 1, 2025
Study Completion Date
December 30, 2025
PCSK9 Antibody, PCSK9 Enzyme
In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
LifeBridge Health
OTHER